ArticleInternational journal of molecular sciences2026
Prehabilitation as a Strategy to Modulate the Tumor Microenvironment in Pancreatic Cancer.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodal prehabilitation aims to enhance resilience to cancer therapy through exercise, nutrition, and psychological optimization. While prehabilitation can improve physical condition and functional status, its biologic influence on the tumor microenvironment (TME) remains poorly characterized. In pancreatic ductal adenocarcinoma (PDAC), the TME is dominated by immunosuppressive and desmoplastic features that limit immune cell infiltration and therapeutic efficacy. As an exploratory pilot analysis, this study characterized the cellular composition, spatial relationships, and functional signaling of the pancreatic TME in patients who underwent prehabilitation prior to surgical resection and those who did not. Tumor samples from eight patients (four prehabilitation, four control) were analyzed with a 34-plex protein panel using Imaging Mass Cytometry (IMC), categorizing the tumor-immune landscape and functional status at the single-cell resolution. Prehabilitation tumors demonstrated reduced neutrophil and epithelial/tumor cell density and enrichment of Natural Killer (NK), CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.